Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 7:9:2043.
doi: 10.3389/fimmu.2018.02043. eCollection 2018.

The Treatment of Activated PI3Kδ Syndrome

Tanya I Coulter  1 , Andrew J Cant  2
Affiliations
Review

The Treatment of Activated PI3Kδ Syndrome

Tanya I Coulter et al. Front Immunol. .

Abstract

Activated phosphoinositide 3-kinase δ syndrome (APDS), also known as PASLI disease (p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency) are combined immunodeficiencies resulting from gain-of-function mutations in the genes (PIK3CD and PIK3R1) encoding the subunits of phosphoinositide 3-kinase δ (PI3Kδ) and were first described in 2013. These mutations result in the hyperactivation of the PI3K/AKT/mTOR/S6K signally pathways. In this mini-review we have detailed the current treatment options for APDS. These treatments including conventional immunodeficiency therapies such as immunoglobulin replacement, antibiotic prophylaxis, and hematopoietic stem cell transplant. We also discuss the more targeted therapies of mTOR inhibition with sirolimus and selective PI3Kδ inhibitors.

Keywords: APDs; HSCT; PASLI; activated PI3 kinase delta syndrome; primary immunodeficiency.

PubMed Disclaimer

References

    1. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. . Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science (2013) 342:866–71. 10.1126/science.1243292 - DOI - PMC - PubMed
    1. Jung S, Gámez-Díaz L, Proietti M, Grimbacher B. “Immune TOR-opathies,” a novel disease entity in clinical immunology. Front Immunol. 9:966. 10.3389/fimmu.2018.00966 - DOI - PMC - PubMed
    1. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. . Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. (2014) 15:88–97. 10.1038/ni.2771 - DOI - PMC - PubMed
    1. Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. . Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study. J Allergy Clin Immunol. (2017) 139:597–606.e4. 10.1016/j.jaci.2016.06.021 - DOI - PMC - PubMed
    1. Elkaim E, Neven B, Bruneau J, Mitsui-Sekinaka K, Stanislas A, Heurtier L, et al. . Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: a cohort study. J Allergy Clin Immunol. (2016) 138:210–8.e9. 10.1016/j.jaci.2016.03.022 - DOI - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources